Active Pharmaceutical Ingredients/API Market worth 213.97 Billion USD by 2021
This report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).
Seattle, The United States – August 30, 2017 /MarketersMedia/ —
Browse 369 market data tables and 46 figures spread through 312 pages and in-depth TOC on “Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) – Global Forecast to 2021”
http://www.marketsandmarkets.com/Market-Reports/API-Market-263.html
Early buyers will receive 10% customization on this report.
The global active pharmaceutical ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021.
On the basis of type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment is estimated to command the largest share in 2016.
Some of the major factors contributing to its large share include growing demand for innovative therapeutics for treatment of dreadful diseases, especially cancer, the increase in the number of FDA approvals for new molecular entities and the higher prices of innovative APIs (as compared to generics). On the basis of type of manufacturer, the active pharmaceutical ingredients market is segmented into captive and merchant API manufacturers.
The APIs market, on the basis of type of synthesis, is segmented into synthetic and biotech APIs. Synthetic APIs is estimated to dominate this market in 2016.
Download the PDF Brochure@
http://www.marketsandmarkets.com/pdfdownload.asp?id=263
The large share of this segment can be attributed to the emergence of new synthetic molecules in the market, increasing number of new product approvals, less complex manufacturing and approval processes as compared to biologics and technological advancements in the method of synthesis.
However, the biotech APIs market is expected to grow at a substantially higher rate during the forecast period owing to advances in biotechnology, growing demand for biopharmaceuticals due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies.
Based on product, the biotech active pharmaceutical ingredients market is segmented into monoclonal antibodies, hormones, vaccines, cytokines, fusion proteins, therapeutic enzymes, and blood factors.
In 2015, the monoclonal antibodies segment account accounted for the largest share of the global biotech active pharmaceutical ingredients market. Growing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and increasing application of mAbs in oncology reduced side effects as compared to chemotherapy are some of the major factors responsible for the large share of monoclonal antibodies in this market.
Get the Sample Pages@
http://www.marketsandmarkets.com/requestsample.asp?id=263
Based on geography, the global active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors including increasing incidence of chronic diseases, increasing focus of the government on the growing adoption of generic drugs, rising demand for biologics and specialty drugs, and technological advances in API manufacturing.
Prominent players in the active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.) and AbbVie Inc. (U.S.).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com
Contact Info:
Name: Mr. Rohan
Organization: MarketsandMarkets
For more information, please visit http://www.marketsandmarkets.com/
Source: MarketersMedia
Release ID: 234613
Copyright © 1999-2013 SproutNews.com
